Spruce Biosciences, Inc.
tralesinidase alfa
Sanfilippo Syndrome Type B (MPS IIIB)
Resolved
152days ago
Phase 2 readout · Feb 5, 2026
What's at stake
Phase 2 trial results for tralesinidase alfa in Sanfilippo Syndrome Type B (MPS IIIB) are due Feb 5, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“The Presentation included final results from the Company’s new analyses of its existing data from Observational Study 902 and Interventional Studies 250-201, 250-202, and 250-401 for the treatment of MPS IIIB using the validated Vineland Ad”